Sanofi Invests €300M in Orano Med for Next-Generation Radioligand Therapies

Partnership:
Sanofi and Orano Med have entered into an agreement to develop next-generation radioligand medicines for rare cancers, focusing on targeted alpha therapies using lead-212 (212Pb).

Investment:
Sanofi is investing €300 million in Orano Med, acquiring a 16% stake in the company to accelerate the development of radioligand therapies.

Licensing Agreement:
Sanofi, RadioMedix, and Orano Med have an exclusive licensing agreement for the late-stage project AlphaMedix, a radioligand therapy for treating adult patients with unresectable or metastatic neuroendocrine tumors (NETs).

Breakthrough Therapy Designation:
AlphaMedix has been granted Breakthrough Therapy Designation for gastroenteropancreatic neuroendocrine tumors (GEP-NETs), highlighting its potential as a transformative radioligand therapeutic.

Manufacturing and Commercialization:
Orano Med will be responsible for manufacturing AlphaMedix through its global industrial platform, while Sanofi will handle global commercialization.

Financial Terms:
RadioMedix and Orano Med will receive an upfront payment of €100 million and up to €220 million in sales milestones, along with tiered royalties.